Angiochem Inc of Canada has secured a new global collaboration with GlaxoSmithKline Plc to develop a new enzyme replacement therapy for a lysosomal storage disease. The deal features an upfront payment of up to $31.5 million. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
